Kairos Pharma Files for Public Offering
Ticker: KAPA · Form: S-1 · Filed: Apr 22, 2025 · CIK: 1962011
Sentiment: neutral
Topics: ipo, pharmaceutical, registration
TL;DR
Kairos Pharma just filed to go public. Get ready for IPO.
AI Summary
Kairos Pharma, Ltd. filed an S-1 registration statement on April 21, 2025, to offer its securities to the public. The company, incorporated in Delaware with its principal executive offices at 2355 Westwood Blvd., #139, Los Angeles, CA 90064, operates in the Pharmaceutical Preparations industry (SIC 2834). The filing indicates an intention to go public, with John S. Yu, M.D. serving as Chief Executive Officer.
Why It Matters
This S-1 filing signals Kairos Pharma's intent to become a publicly traded company, which could lead to increased capital for research and development and potentially make its stock available for broader investment.
Risk Assessment
Risk Level: medium — As a company filing for an initial public offering, Kairos Pharma is in a pre-revenue or early-stage phase, carrying inherent risks associated with new market entrants and pharmaceutical development.
Key Numbers
- 2834 — SIC Code (Identifies Kairos Pharma's industry as Pharmaceutical Preparations.)
- 462993314 — EIN (Employer Identification Number for Kairos Pharma, Ltd.)
- 333-286662 — SEC File Number (The SEC's file number for this registration.)
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- 2355 Westwood Blvd., #139, Los Angeles, CA 90064 (location) — Principal Executive Offices
- John S. Yu, M.D. (person) — Chief Executive Officer
- Dorsey & Whitney LLP (company) — Legal Counsel
- Megan J. Penick, Esq. (person) — Legal Counsel
- April 21, 2025 (date) — Filing Date
FAQ
What is the primary business of Kairos Pharma, Ltd.?
Kairos Pharma, Ltd. is in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Who is the CEO of Kairos Pharma, Ltd.?
John S. Yu, M.D. is the Chief Executive Officer of Kairos Pharma, Ltd.
Where are Kairos Pharma's principal executive offices located?
The principal executive offices of Kairos Pharma, Ltd. are located at 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
When was this S-1 filing submitted?
This S-1 registration statement was filed with the SEC on April 21, 2025.
What is the state of incorporation for Kairos Pharma, Ltd.?
Kairos Pharma, Ltd. is incorporated in Delaware.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on April 22, 2025 by John S. Yu, M.D. regarding Kairos Pharma, LTD. (KAPA).